Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir vs Valganciclovir Prophylaxis in Kidney Transplant Recipients
NCT07294547Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2029
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised trial of valaciclovir in cytomegalovirus infection (CMV) and Epstein-Barr virus infection (2 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Time to new-onset CMV viremia at 2 years, Time to new-onset EBV viremia at 2 years and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
valaciclovir
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07294547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294547.